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RESEARCH ARTICLE
Restoration of mutant bestrophin-1 expression, localisation and
function in a polarised epithelial cell model
Carolina Uggenti, Kit Briant, Anne-Kathrin Streit, Steven Thomson, Yee Hui Koay, Richard A. Baines,
Eileithyia Swanton*,‡ and Forbes D. Manson*,‡
ABSTRACT
Autosomal recessive bestrophinopathy (ARB) is a retinopathy
caused by mutations in the bestrophin-1 protein, which is thought to
function as a Ca2+-gated Cl− channel in the basolateral surface of
the retinal pigment epithelium (RPE). Using a stably transfected
polarised epithelial cell model, we show that four ARB mutant
bestrophin-1 proteins were mislocalised and subjected to
proteasomal degradation. In contrast to the wild-type bestrophin-1,
each of the four mutant proteins also failed to conduct Cl− ions
in transiently transfected cells as determined by whole-cell
patch clamp. We demonstrate that a combination of two clinically
approved drugs, bortezomib and 4-phenylbutyrate (4PBA),
successfully restored the expression and localisation of all
four ARB mutant bestrophin-1 proteins. Importantly, the Cl−
conductance function of each of the mutant bestrophin-1 proteins
was fully restored to that of wild-type bestrophin-1 by treatment
of cells with 4PBA alone. The functional rescue achieved with
4PBA is significant because it suggests that this drug, which
is already approved for long-term use in infants and adults,
might represent a promising therapy for the treatment of ARB
and other bestrophinopathies resulting from missense mutations
in BEST1.
KEYWORDS: Autosomal recessive bestrophinopathy, Bestrophin-1,
Chemical chaperone, 4-phenylbutyrate
INTRODUCTION
Bestrophin-1 is a homopentameric channel protein primarily
expressed in the basolateral membrane of the retinal pigment
epithelium (RPE) (Marmorstein et al., 2000; Kane Dickson
et al., 2014). Over 250 variants in the bestrophin-1 gene, BEST1,
are associated with a group of retinal degenerative diseases
collectively known as bestrophinopathies [Best disease, autosomal
dominant vitreoretinochoroidopathy, retinitis pigmentosa (RP),
autosomal recessive bestrophinopathy (ARB)] (Burgess et al.,
2008). All the bestrophinopathies are associated with abnormal
RPE function as measured by an electro-oculogram, but the
effect on retinal function and the age of onset is variable (Boon
et al., 2009).
The endogenous activity of bestrophin-1 remains unclear.
Exogenous expression of bestrophin-1 results in a novel Ca2+-
activated Cl− current (Sun et al., 2002); it is also highly permeable to
HCO3 (Qu and Hartzell, 2008) and has been reported to act as a
glutamate channel in hippocampal astrocytes (Woo et al., 2012).
These data, together with the crystal structure of bestrophin-1
orthologues, suggest that it is an anion channel (Kane Dickson et al.,
2014). A common consequence of mutations in bestrophin-1 is
aberrant localisation and reduced stability of the mutant proteins
(Davidson et al., 2011; Johnson et al., 2014). ARB is an autosomal
recessive disease and the associated missense mutations have a loss-
of-function effect on bestrophin-1 activity. In previous studies into
bestrophin-1 mutations associated with ARB we found that all of the
nine mutant proteins we tested had a significantly smaller Cl−
conductance compared with wild-type (WT) bestrophin-1 (Burgess
et al., 2008; Davidson et al., 2009, 2011). In addition, most mutant
proteins were mislocalised (7 of 9 examined), and had reduced
stability resulting from proteasomal degradation (6 of 9 examined)
(Burgess et al., 2008; Davidson et al., 2009, 2011). Thus, these ARB-
associated mutations seem to disrupt bestrophin-1 function, at least in
part, by disrupting the protein’s folding, leading to retention and
degradation by the quality control systems that eliminate misfolded
proteins from the secretory pathway (Christianson and Ye, 2014).
Some mutant proteins, including ion channels, retain functional
activity and can be rescued from their misfolded state by chemical
compounds that enhance the capacity of cellular protein folding
pathways (proteostasis regulators) or stabilise protein folds
(chemical and pharmacological chaperones). Such approaches
have shown success in the laboratory for a variety of genetic
diseases including α1-anti-trypsin deficiency, cystic fibrosis, and
Huntington’s disease, using compounds such as 4-phenylbutyrate
(4PBA), carbamazepine and celastrol (Lim et al., 2004; Singh
et al., 2008; Puls et al., 2013; Cleren et al., 2005). In the context
of eye diseases, treatment with the chemical chaperone
tauroursodeoxycholate (TUDCA) preserved retina function and
structure in rodent models of Bardet–Biedl syndrome, RP and Leber
congenital amaurosis (Drack et al., 2012; Phillips et al., 2008;
Zhang et al., 2012; Fernández-Sánchez et al., 2011), whilst the
application of topical 4PBA restored normal intraocular pressure
in a transgenic myocilin mouse model of primary open angle
glaucoma (Zode et al., 2012). These recent advances suggest that
manipulation of the cell’s protein folding pathways might also
present an opportunity to restore mutant bestrophin-1 localization
and/or function.
Here, we report the use of chemical chaperones and proteostasis
regulators to enhance the expression of ARB mutant bestrophin-1
proteins, correct their trafficking to the plasma membrane, and
restore Cl− conductance functionality.Received 27 November 2015; Accepted 21 July 2016
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RESULTS
ARB-associated mutations disrupt bestrophin-1 expression
and localisation in polarised epithelial cells
In order to provide a cellular model with which to examine the ability
of selected compounds to rescue mutant bestrophin-1 expression and
localisation, we generated tetracycline-inducible MDCKII cell lines
stably expressing WT bestrophin-1 and four ARB-associated
mutants (p.L41P, p.R141H, p.R202W and p.M325T). MDCK II
cells adopt a polarised morphology typical of epithelial cells that
we and others have shown can recapitulate the authentic localisation
of WT bestrophin-1 (Mostov et al., 2003; Davidson et al., 2009;
Milenkovic et al., 2011; Doumanov et al., 2013; Johnson et al.,
2013). MDCKII stable cells lines were grown on Transwell porous
filters for 5-6 days until they formed a confluent monolayer, then
bestrophin-1 expression was induced by addition of tetracycline.
After 24 h of induction, bestrophin-1 protein could be detected in
cell lysates as a single band at the expected molecular mass of
68 kDa by immunoblotting with a monoclonal anti-bestrophin-1
antibody (Fig. 1A, lane 2). Bestrophin-1 was not observed in the
absence of tetracycline (Fig. 1A, lane 1), confirming that transgene
expression was tightly regulated and that MDCKII cells do not
express detectable levels of endogenous bestrophin-1. Indirect
confocal immunofluorescence microscopy confirmed that the
MDCKII cells were polarised, and that WT bestrophin-1 was
localised to the basolateral surfaces of the plasmamembranewhere it
co-localised with MCT-1 (Fig. 1B, panel 2). In addition, some WT
bestrophin-1 staining was observed intracellularly (Fig. 1B, panel 2),
suggesting that a proportion of the protein did not reach the cell
surface. This might reflect the native distribution of bestrophin-1
(Barro-Soria et al., 2010), or could indicate that a fraction of nascent
WT bestrophin-1 does not fold correctly inMDCKII cells and is thus
retained by intracellular quality control systems. Consistent with the
latter interpretation, the expression level of WT bestrophin-1 was
significantly increased by treating cells with the proteasome inhibitor
PSII [(benzyloxycarbonyl)-Leu-Leu-phenylalaninal] following
tetracycline induction (Fig. 1A, lane 4; Fig. S1). In contrast,
inhibition of lysosomal proteases using a combination of leupeptin
and pepstatin A caused only a small, non-significant, increase inWT
bestrophin-1 levels (Fig. 1A, lane 3; Fig. S1). Together, these results
confirm previous findings that MDCKII cells are able to support
proper folding and basolateral transport of WT bestrophin-1, but
indicate that a proportion of the WT protein is targeted for
proteasomal degradation.
In comparison with the WT protein, extremely low levels of
p.L41P, p.R141H, p.R202W and p.M325T bestrophin-1 were
detected in lysates of MDCKII cell lines stably transfected with
these mutant constructs, even after 24 h of tetracycline induction
(Fig. 1A, lanes 6, 10, 14, 18). Immunofluorescence microscopy
revealed only faint bestrophin-1 staining in these stable cell lines
(Fig. 1B, panels 3-6), consistent with low expression levels of the
mutant proteins. Furthermore, none of the bestrophin-1 mutants co-
localised with MCT-1 at the basolateral membrane, but were instead
observed in distinct intracellular structures (Fig. 1B, panels 3-6).
Comparable levels of WT and mutant bestrophin-1 mRNA were
detected following induction with tetracycline (Fig. 1C), suggesting
that the observed differences in protein expression did not reflect
altered transcription or mRNA stability. In order to determine
whether the reduced steady-state levels of the mutant proteins were
instead the result of proteolytic degradation of mislocalised
bestrophin-1, cells were induced with tetracycline then treated
with inhibitors of proteasomal and lysosomal degradation pathways
for 6 h. Inhibition of lysosomal proteases did not significantly affect
levels of any of the four mutant bestrophin-1 proteins (Fig. 1A, lanes
7, 11, 15 and 19; Fig. S1). However, treatment with the proteasome
inhibitor PSII led to a dramatic and significant increase in the
amount of each of the mutant bestrophin-1 proteins that could be
detected by immunoblotting (Fig. 1A, lanes 8, 12, 16 and 20;
Fig. S1). Together, these results suggest that the four ARB-
associated mutations disrupt the folding of bestrophin-1, leading to
retention by intracellular quality control systems and degradation
via a proteasome-dependent pathway such as ER-associated
degradation (ERAD). Similar mechanisms have been shown to
limit the expression of a wide range of mutant membrane proteins
(Sano and Reed, 2013; Ng et al., 2012), and suggest a model
whereby a lack of functional bestrophin-1 protein underlies ARB.
We noted that the accumulated mutant bestrophin-1 following
treatment with PSII appeared as a doublet upon SDS-PAGE and
immunoblotting, with the additional band being of a slightly greater
apparent mass than that detected in untreated cells (Fig. 1A, compare
second and fourth lane of each mutant). Bestrophin-1 does not
contain any consensus sites for N-glycosylation within its luminal/
extracellular domains, and we tested whether this higher molecular
weight band was the result of post-translational modification by
phosphorylation or mannosylation, but were unable to demonstrate
that either modification was present (data not shown). Hence, the
nature of this additional form is presently unknown, but as it was also
observed upon proteasome inhibitor treatment of cells expressingWT
bestrophin-1 (Fig. 1A, compare lanes 2 and 4), it seems likely that it
represents a feature of the WT protein.
The proteasome inhibitor bortezomib (BTZ, also known as
Velcade) is currently in use for the treatment of multiple myeloma
(Field-Smith et al., 2006), and we tested whether this inhibitor was
also able to restore expression levels of mutant bestrophin-1. Indeed,
treatment of cells with 25 nM BTZ substantially increased the levels
of all four ARB-associated bestrophin-1 mutant proteins (Fig. 2A-D,
lane 3), providing further evidence that they are targeted for ERAD.
However, for all four mutant bestrophin-1 proteins the majority of the
protein remained intracellular. Inhibiting degradation can in some
cases be sufficient to promote proper folding and trafficking of
mutant proteins (Wang and Segatori, 2013). This seems to be partly
true for the mutant proteins p.L41P and p.R141H, which showed
some co-localisationwithMCT-1 followingBTZ treatment, although
most of the mutant protein still seemed to be intracellular (Fig. S2).
Similarly, a proportion of p.L41P bestrophin-1 localises to the
basolateral membrane of transiently transfected MDCKII cells in the
absence of proteasome inhibitors (Davidson et al., 2011; Johnson
et al., 2014). These results indicate that degradation of p.L41P and
p.R141H bestrophin-1 competes with productive folding, and that
reducing degradation or increasing expression level (e.g. using
transient transfection, which typically results in higher expression)
allows a small pool of the mutant protein to fold and traffic to the cell
surface. Although exposure to BTZ also increased the expression
levels of the other two mutant proteins, p.R202W and p.M325T,
they remained predominantly intracellular and did not co-localise
extensively withMCT-1 (Fig. S2). These data support the conclusion
that mutant bestrophin-1 is degraded by ERAD and suggest that
increasing the cellular concentration of mutant bestrohin-1 is not
sufficient to effectively rescue folding and restore proper localisation.
Restoration of mutant bestrophin-1 expression and
localisation
We next examined whether simultaneously inhibiting proteasomal
degradation and enhancing folding using chemical chaperones or
proteostasis regulators would allow rescue of mutant bestrophin-1
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Fig. 1. Expression of WT and ARB-associated bestrophin-1 in stable MDCKII cells. (A) MDCKII cells were grown on Transwell filters until they formed a
confluent, polarised monolayer, then WT or mutant p.L41P, p.R141H, p.R202W and p.M325T bestrophin-1 expression was induced with tetracycline (Tet) for 24 h
before direct lysis in SDS sample buffer for western blotting analysis. Cells were tested for the expression of bestrophin-1 in presence or absence of tetracycline,
lysosomal protease inhibitors (LI) and proteasome inhibitors (PI). An anti-tubulin antibody was used as a loading control. The expression of WT bestrophin-1 was
significantly increased by treating cells with PI following Tet induction (untreated, n=3; PI-treated, n=3; P=0.0189 by one-way ANOVA, followed by Bonferroni multi-
comparison test). PI treatment led to a significant increase in the amount of each of the mutant bestrophin-1 proteins (p.L41P with and without PI, n=3, P=0.0012;
p.R141H with and without PI, n=3, P=0.0042; p.R202W with and without PI, n=3, P=0.0107; p.M325T with and without PI, n=3, P=0.0037; analysed by one-way
ANOVA, followed by Bonferroni multi-comparison test). (B) Localisation of WT or ARB-causing bestrophin-1 was determined by confocal immunofluorescence
microscopy. Cells were fixed with 4% PFA, permeabilised with 0.1% Triton X-100 and stained for bestrophin-1 (green) and monocarboxylate transporter 1 (MCT1,
red), which was used as amarker for the basolateral plasmamembrane. RepresentativeXYandXZ scans are shown. Scale bar: 5 µm. l, lateral; b, basal. Dotted line
in merged images shows position of the XZ scan. (C) Relative WT and mutant BEST1 mRNA levels were determined for stable MDCKII lines before and after
tetracycline induction by semi-quantitative RT-PCR. Data are expressed relative to GAPDH and are representative of three independent replicates.
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localisation (Mu et al., 2008; Wang et al., 2011). Cells were induced
to express bestrophin-1 and treated with a combination of BTZ plus a
chemical chaperone or proteostasis regulator for 24 h. At a qualitative
level, each of the four bestrophin-1 mutant proteins examined was
affected in a similar way by these combinatorial treatments (Fig. 2).
Notably, the chemical chaperone 4PBA (2.5 mM) in combination
with BTZ caused a further increase in the cellular levels of each
mutant protein, above that seen with BTZ alone (Fig. 2A-D, compare
lanes 3 and 4). A similar effect was also seen with WT bestrophin-1
(data not shown). The detection of intracellular WT protein after
induction (Fig. 1B, panel 2), and its increased expression after
treatment with the chemical chaperone 4PBA (Fig. S3), suggest
that a proportion of the WT protein is misfolded. In contrast,
the other chemical chaperones trimethylamine N-oxide (TMAO,
50 mM; Fig. 2A-D, lane 5) and TUDCA (1 mM; data not shown)
and the proteostasis regulators 17-AAG (17-N-allylamino-17-
demethoxygeldanamycin) (50 nM; Fig. 2A-D, lane 6) and celastrol
(50 nM; data not shown) did not appreciably alter expression levels of
mutant bestrophin-1, either alone or in combination with BTZ. 4PBA
is a low molecular weight chemical chaperone that non-specifically
stabilises native protein folds, and thus enhances the productive
folding and trafficking of a number of folding-defective mutant
proteins (Powers et al., 2009). The observation that the treatment of
cells with 4PBA increased the expression levels ofmutant bestrophin-
1 indicates that it promotes folding of these disease-associated mutant
proteins, thereby reducing their degradation by ERAD.
Because correctly folded bestrophin-1 is transported to the
basolateral surface, we examined the subcellular localisation of
bestrophin-1 in cells treated with different small molecules. Of the
treatments tested we observed that the combination of BTZ plus
4PBAwas able to partially restore cell surface localisation to each of
the bestrophin-1 mutants (Fig. 2E). Although much of the mutant
bestrophin-1 remained intracellular, an increased amount of the
mutant protein was also observed at the plasma membrane (Fig. 2E,
bottom two rows). This is most evident in the XZ projections, where
bestrophin-1 is clearly seen to co-localise with MCT-1 on the
Fig. 2. Small molecule treatment of ARB-associated
bestrophin-1 in stable polarised MDCKII cells. (A-D) Mutant
bestrophin-1 proteins expression level was investigated by western
blot. p.L41P, p.R141H, p.R202W and p.M325T bestrophin-1
expression was induced with tetracycline (Tet) and cells were
treated with BTZ or a combination of BTZ+4PBA, TMAO or 17-AAG
for 24 h before direct lysis in SDS sample buffer. An anti-tubulin
antibody was used as a loading control. (E) Confocal
immunofluorescence analysis was used to investigate mutant
bestrophin-1 localisation (green) in MDCKII stable cells lines
following 24 h treatment with BTZ+4PBA. Representative XY and
YZ scans for each mutant are shown. Co-localisation with MCT-1
(red) was used as a marker for correct trafficking to the basolateral
plasmamembrane. Scale bar: 5 µm. l, lateral; b, basal. Dotted line in
merged images shows position of the XZ scan.
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basolateral surface (Fig. 2E, bottom row). We conclude that in
the presence of BTZ, treatment with 4PBA is able to promote the
correct folding and trafficking of mutant bestrophin-1, so restoring
its cell surface localisation.
Restoration of mutant bestrophin-1 function
Having established that mutant bestrophin-1 could be rescued from its
misfolded state to allow trafficking to the cell surface, we next
examined whether the mutated proteins were functional. The best-
characterised activity of bestrophin-1 is as an anion channel (Sun
et al., 2002; Davidson et al., 2011, 2009). Expression of WT
bestrophin-1 induces an exogenous Cl− conductance in HEK293
cells that can be measured by whole-cell patch clamp. We therefore
transiently transfected HEK293 cells with the WT and four ARB
mutant bestrophin-1 constructs and measured the Cl− conductance in
the absence and presence of small molecules. Fig. 3C shows themean
current-voltage relationship obtained from cells transfected with WT
bestrophin-1 or, in control cells, transfected only with GFP (a marker
Fig. 3. Whole-cell patch clamp of transiently transfected HEK293 expressing WT and mutant bestrophin-1 after treatment with 4PBA. Representative
whole-cell current responses of HEK293 cells transiently transfected with WT (A,B) or p.M325T (D,E) bestrophin-1 treated with 2.5 mM 4PBA. Recordings were
taken from−120 mV to +80 mV in Δ20 mV steps of 450 ms each. The conductance in cells expressing p.M325Twas increased from 48.9±23.1 mA (mean±s.e.m.,
n=3) in the absence of 4PBA to 1118.7±330.8 pA (n=5) following 4PBA treatment (P<0.0001 by two-way ANOVA, followed Turkeymulti-comparison test). TheCl−
conductance induced by p.M325T in the presence of 4PBAwas not significantly different to that that induced by WT bestrophin-1 (580.6±98.7 pA). The holding
potential was −50 mV. The mean current/voltage relationship (I/V) is shown for cells transfected with WT with and without 4PBA treatment, compared with
transfection with GFPonly (C). (I) Plot of Cl− conductance (pA) at a holding potential of +80 mV forWTand 4ARB-causingmutants before and after treatment with
2.5 mM 4PBA. Results are presented as mean±s.e.m. *P<0.05, **P<0.01 and ***P<0.001 indicate significant differences between treated and untreated cells by
one-way ANOVA, followed by Bonferroni multi-comparison test. n, number of cells recorded in independent experiments; NT, not treated (−4PBA).
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for successful transfection). WT bestrophin-1 produced a large time-
independent Cl− current with a slightly outwardly rectifying I-V
relationship (Fig. 3A). Non-transfected cells produced a very small
Cl− current, comparable with that produced by cells transfected
with GFP alone (Fig. 3G,H), and in both cases the Cl− current was
significantly less than obtained following transfection with WT
bestrophin-1 (Fig. 3A,G,H). Cl− currents in cells transiently
expressing the four ARB bestrophin-1 mutants were notably
reduced compared with those induced by the expression of WT
bestrophin-1 at all positive holding potentials (Fig. 3D,F,I; Fig. S4).
Interestingly, however, the reversal potentials for the small currents
induced by the mutant proteins were comparable with that of the WT
bestrophin-1-induced current of −17.6±0.87 mV (mean±s.e.m.)
(Fig. 3F; Fig. S4). This observation is consistent with the reduction
in Cl− conductance by the ARB-associated mutant proteins resulting
from fewer active channels in the cell membrane rather than a change
to voltage sensitivity or channel kinetics of the mutant proteins.
As reported previously (Milenkovic et al., 2009; Davidson et al.,
2009), the large majority of WT bestrophin-1 transiently expressed in
HEK293 cells failed to reach the plasma membrane but was instead
retained intracellularly (Fig. S5). The very large amounts of
intracellular protein precluded detection of bestrophin-1 at the
surface of HEK293 cells, and therefore it was not possible to
determine whether the mutants had reduced cell surface localisation
using immunofluorescence microscopy. Instead, we examined the
relative abundance of WT and mutant bestrophin-1 channels at the
plasma membrane of HEK293 cells using cell surface biotinylation
experiments. Cells expressing WT or mutant forms of bestrophin-1
were treated with a membrane-impermeable biotinylation reagent
in order to selectively modify proteins on the cell surface.
The biotinylated proteins were then isolated by binding to
streptavidin-agarose beads, and subjected to immunoblotting with
anti-bestrophin-1 antibodies. A considerable amount of WT
bestrophin-1 was observed in the streptavidin pull-downs (Fig. 4A,
lane 8), consistent with it being expressed on the surface of HEK293
cells and thus accessible for biotinylation. By comparison, very little
biotinylated bestrophin-1 was detected in cells expressing the ARB
mutants (Fig. 4A, lanes 9-12), despite comparable biotinylation
efficiency, as demonstrated by recovery of biotinylated transferrin
receptor (TfR) (Fig. 4A, lanes 7-12). Thus as observed in MCDKII
cells by immunofluorescence microscopy (Fig. 1), much less of the
ARB-associated bestrophin-1 mutant proteins were present at the
plasma membrane of HEK293 cells compared with the WT
bestrophin-1. These data provide evidence that the decreased Cl−
conductance function of mutant bestrophin-1 observed in HEK293
cells results from lack of cell surface expression of the mutant proteins.
We next examined whether 4PBAwas able to increase levels of mutant
bestrophin-1 at the plasma membrane of HEK293 cells, as seen in
MDCKII cells. Treatment of cells expressing p.M325T bestrophin-1
with 4PBA apparently increased the amount of bestrophin-1 that could
be biotinylated by ∼twofold without obviously affecting the WT
protein (Fig. 4B). Biotinylation of the other three ARB mutants was
also increased following 4PBA treatment (data not shown). However,
the efficiency of bestrophin-1 biotinylation was low, most likely owing
to the small size of its extracellular domains; only 14 out of 585 amino
acids are predicted to be exposed on the cell surface, (Kane Dickson
et al., 2014) and only one of these has a free primary amine group
(lysine 262) available for biotinylation. Thus, this technique might not
be sufficiently sensitive to accurately quantify differences in cell
surface expression of bestrophin-1 following 4PBA treatment.
In order to determinewhether the mutant bestrophin-1 treated with
4PBA was functional, we cultured HEK293 cells expressing
p.M325T bestrophin-1 in the presence of 4PBA for 24 h prior to
measuring Cl− conductance by whole-cell patch-clamp analysis.
Remarkably, treatment with 2.5 mM4PBA for 24 h restoredWT-like
whole-cell current responses in cells expressing the p.M325T mutant
protein (Fig. 3E,F). Cl− conductance was significantly higher in
4PBA-treated cells compared with untreated cells at all holding
potentials (Fig. 3F) and at +80 mV, at which the Cl− currents are
greatest, conductance in cells expressing p.M325T was increased
from 48.9±23.1 mA in the absence of 4PBA to 1118.7±
330.8 pA following 4PBA treatment (Fig. 3E,F). In contrast, 4PBA
treatment did not significantly affect Cl− currents in cells expressing
WT bestrophin-1 (compare Fig. 3A and B; Fig. 3C). Although the
Cl− conductance induced by p.M325T in the presence of 4PBA
(1118.7±330.8 pA) seems to be higher than that induced by WT
bestrophin-1 (580.6±98.7 pA), the difference was not statistically
significant (P=0.469). We also examined the effect of 4PBA on the
three other ARB-associated mutant proteins and found that
restoration of channel activity could also be achieved for p.L41P,
p.R141H and p.R202W bestrophin-1 (Fig. 3I; Fig. S4). Hence, at a
holding potential of +80 mV, Cl− conductance in cells expressing
these mutant proteins was significantly increased in cells treated with
2.5 mM 4PBA compared with untreated cells (Fig. 3I). Although Cl−
conductance by the mutant channels was increased by treatment of
cells with 4PBA, the mean current-voltage relationships show that the
Cl− reversal potentials were unaltered by the compound (Fig. 3C,F;
Fig. S4). These findings are important as they show that the mutant
bestrophin-1 channels rescued by 4PBA are functional and have
similar Cl− conducting properties to the WT protein.
Fig. 4. Biotinylation of WT and mutant bestrophin-1 before and after
treatment with 4PBA in transiently transfected HEK293 cells. (A) Western
blot analysis of whole cell lysates (lanes 1-6) and precipitated biotinylated cell
surface proteins (lanes 7-12) of cells expressing WT or mutant bestrophin-1
proteins. Cells were labelled with biotin for 30 min. The unreacted biotin was
then quenched and the cells lysed. One tenth of the lysate was used for the
total input. Biotinylated (cell surface) proteins were precipitated using
streptavidin beads. (B) Western blot analysis of whole cell lysates (lanes 1-6)
and precipitated biotinylated cell surface proteins (lanes 7-12) of cells
expressing WT or p.M325T bestrophin-1. Cells were grown in absence (lanes
1-3, 5,7-9,11) or presence (lanes 4,6,10,12) of 4PBA for 24 h following
transfection, before labelling with biotin. An anti-transferrin receptor (α-TfR)
antibody was used as a control for the biotinylation assay. An anti-tubulin
antibody was used as loading control. GFP, cells transfected with GFP only;
NT, non transfected cells.
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Whole-cell patch clamp only records currents that flow through
channels in the cell membrane (Gandini et al., 2014). As 4PBA is
known to function as a chemical chaperone, the simplest
interpretation of these findings is that 4PBA promotes folding of
each bestrophin-1 mutant protein to a native-like conformation that
is no longer retained by intracellular quality control systems, leading
to increased expression of functional channels at the cell surface.
However, whilst 4PBA treatment increased the Cl− current induced
by the mutant proteins to values similar to those observed for the
WT protein (Fig. 3I), the amount of mutant bestrophin-1 detected at
the surface was lower than that of the WT (Fig. 4B). This apparent
lack of correlation between levels of bestrophin-1 at the cell surface
and Cl− conductance is most likely the result of inherent differences
in the techniques used to measure these parameters. Hence, data
obtained by analysis of the whole cell population (biotinylation)
might not be directly comparable with analysis of individual highly
expressing cells (patch clamp). However, we also considered the
possibility that the increased Cl− conductance in 4PBA treated cells
could result from an effect of 4PBA on intracellular bestrophin-1
rather than increased transport to the cell surface. To this end, we
placed a dilysine ER-retrieval motif at the C-terminus of bestrophin-1
in order to prevent transport to the cell surface, allowing us to test
whether restoration of Cl− conductance function was indeed the result
of improved trafficking of mutant bestrophin-1. Despite being
expressed at comparable levels with the WT protein (Fig. 5A), Cl−
currents in cells expressing WTKKAA bestrophin-1 were greatly
reduced compared with those induced by the WT protein (Fig. 5B,D).
These results are significant as they demonstrate that Cl− conductance
is specifically induced by cell surface localised bestrophin-1.
Importantly, addition of the ER retrieval motif abolished the effect
of 4PBA on mutant bestrophin-1, as treatment with 4PBA failed to
restore Cl− conductance in cells expressing p.M325TKKAA
bestrophin-1 (Fig. 5E-G). Thus, the ability of 4PBA to rescue
bestrophin-1 Cl− channel activity is dependent upon the protein being
transported along the secretory pathway, further supporting our
hypothesis that this chemical chaperone promotes native folding and
restores functional bestrophin-1 at the plasma membrane.
Alternatively, 4PBA treatment might enhance the activity of mutant,
but not WT, bestrophin-1 (Fig. 3A-C) independently of trafficking/
localisation. In either case, our data clearly demonstrate functional
rescue of mutant bestrophin-1 by treatment of cells with 4PBA. This
rescue of Cl− conductance carried by the ARB mutant proteins
together with the maintenance of the WT reversal potential provide
compelling evidence that targeting protein folding pathways with
compounds such as 4PBA might offer a new therapeutic opportunity
for the treatment of ARB and the other bestrophinopathies resulting
from missense mutations in BEST1.
DISCUSSION
In this study we have restored the function of four bestrophin-1
mutant proteins associated with ARB to that of WT protein using
the chemical chaperone 4PBA. This is a significant advance and
paves theway for translational research using a drug that is approved
for human use.
We previously showed that nine ARB-associated bestrophin-1
mutant proteins have significantly reduced Cl− conductance
compared with the WT protein, and provided evidence that the
loss of function was associated with protein misfolding in the
secretory pathway. Only two of nine mutant proteins correctly
localized to the plasma membrane and six of the nine mutant
proteins were degraded by the proteasome (Burgess et al., 2008;
Davidson et al., 2009, 2011). Here, we have extended this research
using stably transfected MDCKII cells, a polarized epithelial cell
model that represents a model of the RPE. However, as with all
model systems, MDCKII cells have some limitations that might be
relevant to this study, including a lack of endogenous bestrophin-1.
This might also be seen as advantageous for allowing unambiguous
quantification of different cell treatments on the mutant bestrophin-
1 protein under study and avoiding any misinterpretation from
endogenous WT protein. It has also been noted that MDCKII and
RPE cells have variable sorting of MCT1 (Castorino et al., 2011).
Although this will be an important consideration when choosing a
basolateral membrane marker for studies using RPE cells, this fact
has no adverse bearing in this study. We show that both WT and
mutant ARB-associated bestrophin-1 proteins are subject to a
degree of proteasomal degradation and show that the loss of
function of the mutant proteins results from misfolding rather than
having active site mutations. Hence, we were able to rescue the
expression, localization and function of the mutant proteins by
treatment of cells with 4PBA. Induction of exogenous Cl−
conductance in transfected cells is commonly used as a
measurement of bestrophin-1 function, and we demonstrate that
this activity is mediated specifically by bestrophin-1 localised at the
plasma membrane by whole-cell patch clamp. Hence, we propose
that 4PBA promotes native folding and forward trafficking of
mutant bestrophin-1, leading to increased levels of functional
protein at the cell surface. However, the ability of 4PBA to restore
Cl− conductance in p.M325T bestrophin-1-expressing cells was
much greater than its apparent effect on the amount of bestrophin-1
at the cell surface, as detected by biotinylation. Therefore we cannot
exclude the possibility that 4PBA improves the function of mutant
bestrophin-1 already present at the plasma membrane, rather than
promoting forward trafficking of newly synthesised protein. The
mechanism through which 4PBA, a hydrophobic short chain fatty
acid, functions might be related to its activity as a chemical
chaperone, its ability to inhibit histone deacetylases (HDACs)
leading to changes in transcription of genes involved in protein
folding and/or quality control, or a combination of both. In this
respect, it is noteworthy that whilst treatment with an HDAC
inhibitor (tubastatin) had no discernible effect, a second chemical
chaperone, TMAO (50 mM), was able to restore some Cl−
conductance in cells expressing mutant p.M325T bestrophin-1,
albeit to a much lesser extent than 4PBA (data not shown). None of
the other small molecules tested (25 nM BTZ, 1 mM TUDCA,
50 nM 17-AAG, 50 nM celastrol) significantly restored the Cl−
conductance of p.M325T bestrophin-1 (data not shown).
Restoration of mutant protein function using chemical chaperones
has been demonstrated for several proteins including myocilin and
RPE65. In a cell model of RP, chemical chaperones and proteostasis
regulators reduced aggregation of the common rhodopsin p.P23H
mutant, whilst pharmacological chaperones enhanced folding and
reduced the dominant-negative effect of the mutant protein (Mendes
and Cheetham, 2008). Chemical chaperones (glycerol and 4PBA)
have been shown to enhance the low temperature rescue of disease-
associated mutant RPE65 proteins expressed in ARPE-19 cells (Li
et al., 2014). Misfolded mutant α1-antitrypsin fails to be excreted to
the bloodstream and is retained in the ER of liver cells causing liver
injury and emphysema. The addition of 4PBA to human skin
fibroblasts expressing mutant α1-antitrypsin resulted in a fivefold
increase in its secretion compared with untreated cells. In addition,
oral administration of 4PBA to PiZ mice that are transgenic for
mutant human α1-antitrypsin resulted in blood levels of α1-
antitrypsin increasing to 20-50% of those seen in humans and
transgenic PiM mice expressing WT α1-antitrypsin (Burrows et al.,
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2000). There has also been promising progress in cystic fibrosis (CF)
treatment using 4PBA. Treatment of primary cells from individuals
with CF restored forskolin-activated Cl− secretion and the post-
translational modification of ΔF508-CFTR (Rubenstein et al., 1997),
and in vivo, orally administered 4PBA improved the nasal potential
difference response in CF patients with minimal side-effects (Zeitlin
et al., 2002). In a transgenic mouse model of epilepsy expressing a
secretion-defective mutant form of human LGI1, intraperitoneal
injection of 4PBA restored the binding of mutant LGI1 protein to
its receptor ADAM22 and prevented the increased seizure
susceptibility of the mouse model (Yokoi et al., 2015). 4PBA has
also been tested for the treatment of haemoglobin diseases and a
variety of solid tumours (Zeitlin et al., 2002). Thus, the possibility of
using 4PBA for the long-term correction of protein folding and
function for a variety of diseases seems a realistic and achievable
goal, especially as the drug is approved for use in infants and adults
with urea cycle disorders who need to take it daily for life (Zeitlin
et al., 2002; Batshaw et al., 2001).
Fig. 5. Effect of 4PBA on the expression and activity of ER retainedWTand p.M325T bestrophin-1. (A)Western blot analysis and quantification of whole-cell
lysates of HEK293 cells transiently transfected withWT,WTKKAA, p.M325T or p.M325TKKAA bestrophin-1 constructs showed that the addition of a retention signal
did not alter the steady-state levels of bestrophin-1 protein. Data are presented relative to untaggedWT and p.M325T bestrophin-1, which have been normalised
to 1. (B-G) Representative whole-cell current responses of HEK293 cells transiently transfected with WTKKAA or p.M325TKKAA bestrophin-1 constructs before
(B,E) and after (C,F) 4PBA treatment. Recordings were taken from −120 mV to +80 mV in Δ20 mV steps of 450 ms each (voltage protocol shown in B). The
holding potential was −50 mV. The mean current/voltage relationship (I/V) is shown for cells transfected with WTKKAA or p.M325TKKAA with and without 4PBA
treatment (D,G). Also plotted are the I/V relationships for control untagged WT and p.M325T proteins treated with 4PBA. Results are presented as mean±s.e.m.
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The crystal structures of two bestrophin-1 orthologues have been
reported and reveal that bestrophin-1 is a homopentamer (Yang
et al., 2014; Kane Dickson et al., 2014). Based on the structure of
the chicken bestrophin-1 orthologue, the four mutations studied
here lie in different segments of the bestrophin-1 protein. Leucine
41 is in an α-helix in segment S1c, and is the only residue that lies
within the membrane. Arginine 141 is located towards the end of an
α-helix in segment S2d and is intracellular. Arginine 202 and
methionine 325 are both located in structured loops between
α-helices in the intracellular part of the protein (Kane Dickson et al.,
2014). None of the four mutated amino acids studied here are
located close to the channel pore or to the Ca2+-binding residues,
supporting the notion that these mutations alter protein folding
rather than disrupting the active sites of the channel.
Analysis of the amino acid substitutions in the four ARB mutants
studied here support our conclusion that they are likely to disrupt
protein folding. Of the four residues studied, L41 is the least
conserved, being, for example, a phenylalanine in rat, serine in
chicken and Xenopus, and valine in zebrafish. A mutation matrix
for transmembrane proteins gives a score of –1 for a leucine-to-
proline change, indicating that this change is not often seen and
implies there will be a detrimental functional consequence (Betts
and Russell, 2007). Leucine is an acyclic and hydrophobic amino
acid and its replacement with proline, a small ringed amino acid
that uniquely connects twice to the protein backbone, might be
expected to cause a kink in the S1c segment α-helix. The other
three amino acid substitutions have higher mutation matrix scores,
indicating the changes are seen more frequently and are
functionally less damaging. Arginine 141 is conserved from
human to zebrafish and the substitution of a positive polar residue
with another of similar properties (histidine) is a relatively
common substitution, with a score of 5 on the mutation matrix.
Arginine 202 is also relatively well-conserved (it is an asparagine
in fugu and zebrafish) and it might be thought that its replacement
with tryptophan, which is unique in terms of its chemistry and size,
would be rare (Betts and Russell, 2007). However, an arginine-to-
tryptophan substitution is also relatively common, with a mutation
matrix score of 5. Lastly, methionine 325 is conserved down to
zebrafish and its substitution with a threonine (a non-polar
hydrophobic amino acid replaced by a polar hydrophobic
residue) has a score of zero on the mutation matrix. Importantly,
the detrimental effects of these diverse mutations on bestrophin-1
localisation and function could all be overcome by treatment with
4PBA, suggesting that this strategy might be applicable to other
disease-causing bestrophin-1 mutants.
However, despite the analysis of the amino acid substitutions, their
position in the three dimensional protein structure, and our data
demonstrating that the mutant proteins are misfolded and undergo
proteasomal degradation, it is still difficult to formulate a unifying
pathogenic mechanism for ARB. Several ARB-associated mutations
are either asymptomatic in the heterozygous state (parents of
individuals with ARB) or are pathogenic (individuals with Best
disease). An example illustrating the ARB conundrum is the
p.R141H mutation, the most common recurring mutation
associated with ARB. It can be asymptomatic in some
heterozygous carriers (Burgess et al., 2008; Iannaccone et al.,
2011; Kinnick et al., 2011; Wittström et al., 2011), whereas in others
it can associated with mildly abnormal electroretinogram (ERG) and
electrooculogram (EOG) results, indicating abnormal functioning of
the photoreceptors and RPE, respectively (Wittström et al., 2011).
Individuals with ARB who are homozygous for p.R141H have either
abnormal or severely abnormal ERGs (Boon et al., 2013). In other
individuals p.R141H acts dominantly and causes Best disease
(Krämer et al., 2000; Lotery et al., 2000). There are also a number
of cases involving compound heterozygous mutations in conjunction
with p.R141H. The second mutation can either seem benign or be
associated with another bestrophinopathy. An individual with ARB
has been reported with p.R141H and p.D312N (Boon et al., 2013); as
discussed above for p.R141H, p.D312N can either be asymptomatic
in carriers or act dominantly in individuals with Best disease (Burgess
et al., 2008; Sodi et al., 2011), giving the situation where two
autosomal dominant mutations occur as compound heterozygous
mutations to cause an autosomal recessive disease. Similar
confounding combinations with p.R141H have also been reported
with p.L41P, p.Y29X, p.P233A and p.I266fsX18 (Burgess et al.,
2008; Schatz et al., 2006; Wittström et al., 2011; Johnson et al.,
2015). Thus, it would seem that the pathogenic mechanism not only
varies from mutation to mutation, but also on what other mutation is
present and as-yet-unidentified factors such as promoter strength,
modifying genes and environment. Another possibility is that it is not
the adult function of bestrophin-1 that is important, but what role it
might have had in development (Boon et al., 2013).
The correction of expression, localization and function for four
mutant bestrophin-1 proteins associated with an inherited eye
disease using a drug that is already approved for human use is a
notable milestone towards future translational research. As 4PBA
has proved safe during long-term daily use, often at high doses, for
children and adults alike, trials to reposition the drug to treat
diseases resulting from protein misfolding might be feasible within
a relatively short timeframe. This research will be an exemplar for
the use of small molecules to rescue other misfolded proteins of the
RPE and retina that cause retinal degenerations.
MATERIALS AND METHODS
Cell culture
MDCKII cell lines were cultured at 37°C, 8% CO2 in Dulbecco’s modified
Eagle’s Medium (DMEM) (Gibco, Paisley, UK) supplemented with 2 mM
L-Glutamine (Sigma, Gillingham, UK), 0.1 mMMEM non-essential amino
acids (Sigma) and 10% (v/v) heat-inactivated foetal bovine serum (Sigma).
HEK293 cells were cultured at 37°C, 5% CO2 in DMEM without sodium
pyruvate (Sigma) supplemented with 10% (v/v) heat-inactivated foetal
bovine serum.
T-REx Flp-In MDCK II cells (a kind gift from Dr Joris Robben, Radboud
University, Nijmegen, The Netherlands) and HEK293 cells (purchased
from ATCC) were tested every three months to ensure they were free from
mycoplasma using the Minerva Biolabs Venor GeM kit (Cambio,
Cambridge, UK).
Transient transfection
HEK293 cells were co-transfected with a bestrophin-1 construct and GFP at
a final concentration of 0.45 µg ml−1 and 0.15 µg ml−1, respectively using
Fugene HD transfection reagent (Promega, Southampton, UK) in OptiMEM
(Gibco). Cells were incubated for 6-8 h at 37°C before replacing transfection
medium with complete DMEM.
Cloning and generation of stable cell lines
The ARB-associated mutations p.L41P, p.R141H, p.R202W, and p.M325T
were cloned into the expression vector pcDNA5/FRT/TO (Life
Technologies, Paisley, UK). These plasmids were co-transfected with
pOG44 into T-REx Flp-In MDCK II cells using Lipofectamine LTX with
Plus Reagent transfection reagent (Life Technologies). Stably expressing
colonies were selected in the presence of 200 µg ml−1 hygromycin.
RT-PCR
Total RNA was extracted using TRIzol Reagent (Fisher Scientific,
Loughborough, UK) according to manufacturer’s instructions. The
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precipitated RNA was washed to remove impurities, dried, resuspended in
DNase/RNase-free water and DNase treated with TURBO DNA-free kit
(Fisher Scientific). First-strand cDNAwas generated form 2 μg of RNA by
using the High-Capacity RNA-to-cDNA kit (Fisher Scientific) according to
manufacturer’s instructions. The standard PCR reaction included 1×
ReddyMix custom PCR Master Mix (Abgene, Fisher Scientific), 0.5 μM
forward and reverse primers, 20 ng of DNA and Milli-Q water (Millipore,
Livingston, UK). The cycling parameters were an initial denature at 94°C for
5 min followed by 15 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for
60 s. The reaction was completed with a cycle of 72°C for 10 min.
Treatment with inhibitors and/or small molecules
Cells were incubated with 10 μM proteasomal inhibitor II (PSII,
(benzyloxycarbonyl)-Leu-Leu-phenylalaninal) (Merck Millipore,
Nottingham, UK) or a combination of 100 μM leupeptin (Enzo Life
Sciences, Exeter, UK) and 1 µg ml−1 of pepstatin A (Sigma) for 5-6 h.
When 25 nM Bortezomib (Velcade) (Selleck Chemicals, Stratech,
Newmarket, UK) was used the incubation time was 16-24 h. Small
molecules [2.5 mM 4PBA (Sigma), 50 mM TMAO (Sigma), 1 mM
TUDCA (Calbiochem, Merck Millipore), 50 nM 17-AAG (Sigma),
50 nM celastrol (Sigma)] were added to the cultured media 24 h prior to
harvesting, fixation or patch clamp analysis.
Whole-cell patch clamp
Whole cell voltage-clamp recordings were performed using borosilicate
glass capillaries GC100F-10 (Harvard Apparatus, Edenbridge, UK) that
were fire-polished to a resistance of 1.3-2 MΩ. The electrophysiology setup
consisted of a MultiClamp 700B amplifier controlled by pCLAMP 10.4
(Molecular Devices, Wokingham, UK). Recordings were sampled at
20 kHz and filtered online at 10 kHz. The intracellular solution
(317.6 osmol) contained: 20 mM CsCl, 10 mM EGTA, 7.2 mM
CaCl2, 2 mM MgCl2, 10 mM HEPES, 10 mM glucose, 110 mM Cs
aspartate, adjusted to pH 7.2 with CsOH. The extracellular solution (339
osmol) contained: 140 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES, 10 mM glucose, 30 mM mannitol, adjusted to pH 7.4 with NaOH.
Only cells showing a GFP signal were used for assessment of current
magnitudes.
Biotinylation assay
HEK293 cells were co-transfected with either WT or mutant bestrophin-1
constructs and GFP. After treatment with the compound of interest, cells
were pre-chilled on ice and labelled with 0.5 mg ml−1 EZ-Link Sulfo-NHS-
SS-biotin (Pierce Biotechnology, Thermo Fisher Scientific, Cramlington,
UK) in PBS/CM (10 mM Na2HPO4, 2 mM KH2PO4, 137 mM NaCl,
2.7 mM KCl, 1 mM CaCl2, 1 mM MgCl2 pH 7.4) for 30 min. Cells were
then washed with PBS/CM and 50 mM NH4Cl in PBS/CM was used to
quench unreacted biotin. Cells were lysed in biotin lysis buffer (50 mM Tris
pH 7.4, 150 mM NaCl, 5 mM EDTA, 1.25% Triton X-100, 0.25% SDS,
1 mM PMSF) and lysates were centrifuged at 8000×g for 15 min to remove
non-soluble debris. 10% of the supernatant was kept for control of total
protein loading and the rest of the lysate was incubated with NeutrAvidin
beads (Thermo Fisher Scientific) for 2.5 h. Beads were then washed three
times in biotin lysis buffer, resuspended in 2× SDS sample buffer and
analysed by SDS-PAGE and western blotting.
SDS-PAGE and western blotting
Protein samples were extracted either in SDS sample buffer with 100 mM
DTT to reduce disulphide linkages or in biotin lysis buffer. Samples were
heated for 10 min at 70°C, loaded onto an 8-10% Tris-glycine
polyacrylamide gel and run alongside ColorPlus pre-stained protein
marker (broad range 7-175 kDa, New England Biolabs, Hitchin, UK).
SDS-PAGE gels were transferred onto nitrocellulose membranes (LI-COR
Biosciences, Cambridge, UK) by wet transfer at 300 mA for 1 h.
Membranes were blocked in 5% milk powder (w/v) in TBS for 1 h
before incubation with primary antibodies anti-bestrophin-1 (clone E6-6)
(1:4000; NB300-164, Novus Biological, Cambridge, UK) and rabbit
polyclonal to beta tubulin (1:4000; ab6046, Abcam, Cambridge, UK) in
2% milk-TBS+0.01% NaN3 solution overnight at 4°C, with constant
mixing. Membranes were washed three times in TBS before labelling with
fluorescently labelled secondary antibodies IRDye 800CW donkey anti-
mouse (1:10,000; 925-32212) and IRDye 680CW donkey anti-rabbit
(1:10,000; 925-68071) (both from LI-COR) in 2% milk-TBS for 1 h at
room temperature (RT); then scanned using an Odyssey Infrared Imaging
System (LI-COR) and quantified using Odyssey Sa software (LI-COR).
Quantification of immunoblots was performed by using the Image Studio
Ver.5.0 software (LI-COR).
Confocal microscopy
MDCKII grown on 0.4 μm Transwell polyester membrane inserts (Corning,
Sigma) were washed with PBS, fixed with 3% paraformaldehyde (w/v in
PBS) for 20 min at RT and permeabilised with 0.1%TritonX-100 for 10 min.
Primary antibodies were incubated for 1 h at room temperature in PBS at the
following dilutions: mouse monoclonal anti-bestrophin-1 (E6-6) at 1:500
(NB300-164, Novus Biological, Cambridge, UK) and rabbit polyclonal to
monocarboxylic acid transporter1 (MCT1) at 1:500 (ab85021, Abcam).
Secondary antibodies Alexa Fluor 488 donkey anti-mouse (1:500; A-21202)
and Alexa Fluor 594 donkey anti-rabbit (1:500; A-21207) (both from
Life Technologies) were incubated for 30 min at room temperature with
100 ng ml−1 4,6-diamidino-2-phenylindoledihydrochloride (DAPI). Transwell
filters were cut out from the inserts and mounted onto microscope slides
with 7 µl of mowiol solution or Prolong Gold anti-fade reagent (Life
Technologies) and sealed with nail varnish. Images were taken using a
Nikon C1 confocal on an upright 90i microscope with a 60×/1.40 Plan Apo
objective and 3× confocal zoom. The confocal settings were as follows:
pinhole 30 μm, scan speed 400 Hz unidirectional, format 1024×1024.
Images for DAPI, FITC and Texas Red were excited with the 405 nm,
488 nm and 543 nm laser wavelengths, respectively. When acquiring 3D
optical stacks the confocal software was used to determine the optimal
number of Z-sections. Only the maximum intensity projections of these 3D
stacks are shown in the results.
Data analysis
Quantitative data collected from at least three separate experiments
were plotted as means with error bars indicating standard error of the
mean (±s.e.m.). Statistically significant differences among groups were
identified by one-way or two-way ANOVA, followed respectively by
Bonferroni or Turkey multi-comparison test, using GraphPad Prism 2D
graphing and statistics software (GraphPad, La Jolla, USA).
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